Clinical Trials — When you participate in a clinical trial you help pave the way for new treatments

What is a clinical trial?
A clinical trial is a critical step in the process of getting a new treatment approved so that it can be given to patients. After a drug is thoroughly tested in a lab, a clinical trial is designed to test it and make sure that it is effective and safe, and has the desired effect on the condition it is intended to treat. Many drugs never get off the ground because there are not enough volunteers. Don’t let that happen with new pancreatitis treatments. You have the power to propel research and development toward a cure! Learn more about what is involved in these pancreatitis clinical trials to see if they are right for you.

WebMAP CP

Researchers at Seattle Children’s Hospital want to learn more about pain management strategies to help youth with chronic pancreatitis. The study might be a good fit for you if you/your child is between 10 and 17 years old and has chronic or acute recurring pancreatitis. Families who participate will answer questions about pain, mood, sleep, and everyday life at 3 times over 9 months and use a website for 8-12 weeks, which might help with managing pain. Families will receive $100 for each completed assessment ($300 in total). Results from this study may help other children who have chronic pain. To participate in this study or learn more, please contact the study team at 1-855-932-6272 or palermolab@seattlechildrens.org.

IMPACT

Researchers at Mayo Clinic and Seattle Children’s Research Institute want to find out about the usefulness of an online pain self-management program for adults with pain from chronic pancreatitis. Adults who participate in the research study will complete an online program called the Pancreatitis Pain Course and complete study assessments. The Pancreatitis Pain Course includes lessons on how to cope with pain, DIY guides, and case stories from people with chronic pancreatitis. This is a remote study and all study procedures will be done over the phone and online. For more information, you can call: 206-884-6312 or email: palermolab@seattlechildrens.org to let them know you are interested in participating! (For emails, please provide a phone number to reach you).

Camostat

Researchers at Stason Pharmaceuticals, are leading a nationwide trial named “Camostat” that is a dose ranging study that will evaluate the efficacy and safety of NI-03 in patients with pancreatitis. This might be a good clinical trial for you if you are between 18 and 85 years old, have the ability to communicate effectively with clinic staff and have already been diagnosed with chronic pancreatitis. Participants must also have a daily worst pain score of at least 4 using the Numeric Rating Scale (NRS) during a 7 day period. Additionally, participants must either not be taking opioids or opioid regimes must only be with a morphine-equivalent dose of not more than 100mg per day. Other exclusions also apply. There are 41 sites for this survey. For more information, you can call Aidan Nuttall at 760-672-2640 or aidan.nuttall@kangenpharma.co.jp or Melissa Summers at 404-271-4419 or melissa.summers@synteract.com

SHARP

Researchers at the Medical University of South Carolina are researching whether a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy is a procedure where doctors used a combination of x-rays and an endoscope (a long flexible lighted tube) to find the opening of the duct where fluid drains out of the pancreas. Adults 18 years and older who have been diagnosed with pancreas divisum, have had at least two episodes of pancreatitis within the last 24 months, and are candidates for the ERCP with sphincterotomy procedure may be eligible to participate. Participants will have follow up visits 30 days after the procedure, 6 months after the procedure, and continuing every 6 months until a maximum follow-up period of 48 months.  There are 16 sites for the trial. For more information, contact Dr. Gregory Cote at 843-792-6999 or cotea@musc.edu.